<DOC>
	<DOC>NCT00699426</DOC>
	<brief_summary>To test the effect of Nexium and probiotics on insulin secretion and cardiovascular risk factors on type 2 diabetic patients. Study Hypothesis: 1. Nexium causes an increased gastrin secretion that increases the insulin secretion and thereby a reduction of HbA1c 2. Probiotics changes the gut flora and bloodpressure 3. Probiotics causes a change in inflammation and thrombosis.</brief_summary>
	<brief_title>The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Type 2 diabetes (WHO criteria) treated with metformin and/or sulfonylureas or diet Males and females between 40 and 70 years HbA1c between 6,010,0 Diabetes duration &gt; 1 year Kidney disease (screatinine above the upper limit of normal range). Liver disease (ALAT increase &gt; 3 times the upper limit of the normal range of ALAT). Macroalbuminuria (urinary albumin excretion of &gt; 300 mg/day). Heart failure(NYHA class lll or lV) Severe neuropathy (symptoms + vibration perception threshold &gt; 50 measured by biothesiometer.) Neutropenia (neutrophil count&lt;2.0x10/l) or anemia (hemoglobin&lt;8mM for men or &lt;7mM for women. Alcohol abuse Drug abuse Severe organic or metabolic diseases including cancer Cpeptide&lt; 0,3 pmol/l Medicine interaction Treatment with insulin PPI or other medications for ulcus diseases Treatment with warfarin or other coumarin derivations Pregnant or breastfeeding women Allergy to medication used in the study Participants may not participate in another clinical intervention trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>